Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
EMPAVELI (Apellis Australia Pty Ltd)
Product name
EMPAVELI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
243 (255 working days)
Active ingredients
pegcetacoplan
Registration type
NCE/NBE
Indication
EMPAVELI (solution for injection) is indicated for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have an inadequate response to, or are intolerant of, a C5 inhibitor.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.